Effect of *Morus alba* against Hyperglycemic and Hyperlipidemetic Activities in Streptozotocin Induced Diabetic Nephropathy

P. Swathi¹, K. Gana Manjusha², M. Vivekanand¹, A. Ramkishan³ and B. Bhavani*²

¹A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India.
²Vignan Institute of Pharmaceutical Technology, Visakhapatnam, India.
³Deputy Drug Controller of India, CDSCO, India.

http://dx.doi.org/10.13005/bbra/2589

(Received: 14 October 2017; accepted: 12 December 2017)

The present study was designed to investigate the antihyperglycemic and hypolipidemic activities of ethanolic leaf extract of *Morus alba* (EMA) in Streptozotocin induced diabetic rats. Blood glucose, serum parameters such as glycated haemoglobin (HbA1c), bilirubin, albumin, creatinine, total protein, urea, lipid profile, and urine parameters such as urine protein, creatinine and volume and renal antioxidant enzymes like SOD, CAT, GSH and MDA were estimated at the end of 12 weeks study period. Kidney histopathology was also done. The treatment with EMA showed significant (p<0.05) reduction in the elevated blood glucose, HbA1c, kidney function parameters and lipid profile in STZ induced diabetic rats. Treatment with EMA exerted improvement in antioxidant enzymes as SOD, CAT, GSH and reduction in MDA level profile in STZ induced diabetic rats. Histopathology reveals, EMA showed marked amelioration of glomerulosclerosis caused by STZ. The activities of *Morus alba* might be due to the presence of antioxidant principles like terpenoids and sterols.

**Keywords:** Diabetes; Blood glucose; Nephropathy; Hyperglycemia; Hyperlipidemia.

---

Diabetes mellitus is a chronic and progressive metabolic disease characterized by hyperglycemia due to insulin deficiency, or resistance, or both. Besides hyperglycemia, several other symptoms, including hyperlipidemia, are involved in the development of microvascular and macrovascular complication of diabetes. According to the latest survey in 219 countries, among people egad 20 to 79 years, 382 million people have diabetes mellitus and it is estimated that this number will reach 592 million in 2035.

¹Diabetic nephropathy (DN) is a major cause of end stage renal failure worldwide. DN has not been traditionally considered an inflammatory disease; however, recent studies have shown that kidney inflammation is crucial in promoting the development and progression of DN. ²

³Reactive oxygen species play an important role in high glucose induced renal injury. ³

Free radicals are capable of damaging cellular molecules, DNA, proteins, and lipids leading to altered cellular functions. Many recent studies...
reveal that antioxidants capable of neutralizing free radicals are effective in preventing experimentally induced diabetes in animal models.\(^4\)

Herbal medicines are naturally occurring; plant-derived substances with minimal or no industrial processing that have been used to treat illness within local or regional healing practices. For a long time, herbal medicines or their extracts have been used to cure various diseases, because plant products are frequently considered to be less toxic and free from side effects than synthetic ones. Therefore, studies with plant extracts are useful to understand their efficacy, mechanism of action and safety for treatment and management of diabetes.

Numerous plants have been reported to possess hypoglycemic activity and diabetic nephropathy. Some reported plant sources are Ginkgo biloba, Fragaria ananassa, Moringa oleifera, Cladophora glomerata, Garcinia indica, Ocimum Gratissimum, Astragalus membranaceus and Trigonella foenumgracum.\(^5\)-\(^9\) Reports indicated herbal inventions play a pivotal role in the treatment of diabetes and diabetic nephropathy.

The present investigation was focused on Morus alba (Moraceae). Morus alba reported pharmacological activities related to in vitro antioxidant activity\(^10\), hypoglycemic activity in alloxane induced diabetic rats as \(\alpha\)-amylase inhibitory activity\(^11\) and protective action on ocular function due to the presence of triterpenes (lupeol) Sterols (\(\alpha\)-Sitosterol), bioflavonoids (rutin, moracetin, quercetin-3-triglucoside and isoquercitrin), coumarins, volatile oil, alkaloids, amino acids and organic acids. Morus alba leaves contain rutin, quercetin and apigenin as bioactive constituents.\(^13\) Considering the antioxidant activity and hypoglycemic properties of Morus alba, this study was designed to evaluate the ameliorator effect of Morus alba on oxidative stress induced diabetic nephropathy in diabetic rats induced by Streptozotocin.

**MATERIALS AND METHODS**

**Plant material**

Fresh leaves of Morus alba (Mulburry) were obtained from the rural areas of Visakhapatnam and identified and authenticated by plant taxonomist, department of Botany, Andhra University, India.

**Preparation of plant extract**

The fresh leaves are washed and cut into small pieces and dried under sunshade for 6'-7 days and coarsely powdered. The powder was extracted using soxhelt apparatus with ethanol 2000 ml. The methanol was distilled condensed using rotatory evaporator and stored in desicato. The powder of the extract was suspended in appropriate solvent system.

**Chemicals**

Streptozotocin was procured from Sigma Co. USA, metformin from USV Limited, Maharashtra, while other chemicals used were of analytical grade obtained from E. Merck and Hi-media, India.

**Animals and treatment**

Male Wistar rats (150–180 gm) were used. These were bred in our animal facility and housed in an air-conditioned room (approximately 22 °C) with controlled lighting 12:12 h light/dark cycle. The animals were maintained with pelleted, while tap water was available ad libitum. The study has got the clearance from the Institutional Animal Ethical Committee (IAEC) the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). Rats were acclimatized to the environment for 15 days prior to the experiment; animals were divided into five groups. Each group contains 6 rats. Fasted animals were deprived of food for at least 16 hr but allowed free access to water. The first group was used as control and received H\(_2\)O as vehicle. The second group received a single dose of STZ (60 mg/kg b.wt) and dissolved in citrate buffer and was divided into four subgroups after establishing of the diabetes for 1 week. The first subgroup was kept as a diabetic control while the second, third, and fourth subgroups received orally 1.0 ml of metformin (500mg/kg b.wt), EMA (150 mg/ kg) and EMA (300 mg /kg) respectively by gastric intubation daily for 12 weeks.

**Preparation of samples**

The rats were then etheranesthetized, decapitated and blood sample collected in plain and heparined tubes. From the clotted blood at room temperature, serum was collected after centrifugation (3000 rpm, 10 min) and used to determine the biochemical parameters. Twenty four hour urine samples were collected using...
metabolic cages and analyzed. The animals were kept individually in metabolic cages, and they were given only water.

The kidney were removed, weighed and placed immediately in ice-cold buffer (0.25M sucrose, 10mM Tris and 0.3 mM EDTA; pH 7.4) and washed thoroughly with distilled water to remove blood. The kidneys were homogenized using a Teflon homogenizer. The total homogenate was used for estimation of lipid profile and MDA. The homogenate was centrifuged (15 min, 15 000 rpm), the whole supernatant removed and frozen at -20 ºC for estimation of antioxidant enzymes.

Biochemical Estimations

Fasting blood glucose levels were estimated by using GOD/POD method. Glycosylated haemoglobin cholesterol and triglyceride (TG) levels and HDL-cholesterol by kit method, bilurubin, total protein and albumin were also estimated. At the end of the 12 week treatment period rats were sacrificed and kidneys were used for histopthological examination.

Enzyme estimations in Kidney

Superoxide dismutase was measured according to the method described by Kakkar et al., 1984; catalase was estimated by the method of Sinha, 1972, reduced glutathione measured by method of Jollow et al., 1974 and melanoldehyde was measured by the method of Ohkawa et al., 1979.

Histopathology

Renal tissues were collected after animal sacrifice, fixed in 10% formalin, processed routinely, and embedded in paraffin. 5-50µm thick sections were prepared and stained with hematoxylin and eosin (H&E) dye for microscopic investigation. The stained sections were examined and photographed under a light microscope.

Statistical analysis

Values are mean±SEM for six rats in each group, and significance of the differences between mean values was determined by Bonferroni-post test. The levels of significance were evaluated with p values.

RESULTS AND DISCUSSION

Tight control of blood glucose can reduce clinical complications in diabetic patients. However, alternative treatment strategies are required to prevent the oxidative stress complications such as diabetes. It is well documented that modulations of oxidative stress through treatment with antioxidants can effectively reduce the development of diabetes.

In the present study, diabetes mellitus was induced in rats through a STZ injection that causes the destruction of 2-cells of islets of Langerhans, as proposed by many authors. This effect was represented in the current study through the elevation of blood glucose in STZ induced diabetic control rats. The administration of EMA showed significant (p<0.05) reduction of blood glucose levels (Table 1) accompanied with reduction in glycosylated hemoglobin levels (Table 2).

Hypercholesterolemia, hypertriglyceridemia and enhanced glomerular lipid synthesis have been implicated in diabetic glomerulosclerosis and known to exercebate kidney diseases. Several groups of hypoglycaemic drugs are currently available to treat Diabetes. The abnormal high concentration of serum lipids in diabetes is mainly due to the increase in the mobilization of free fatty acids from the peripheral depots since insulin inhibits the hormone sensitive lipase. In EMA treated diabetic rats shown to normalize the lipid levels (reduction of TG, TC, LDL, VLDL and elevation of HDL) as compared to the STZ induced hyperlipidemia (elevation of TG, TC, LDL, VLDL and reduction of HDL) both in serum and kidney homogenate as shown in Figure 1 and Figure 2. The hyperglycemic effect of EMA could indirectly be related to beneficial action against diabetic hypercholesterolemia, hypertriglyceridemia.

Diabetic nephropathy in uncontrolled diabetes is a serious micro-vascular complication leading to glycosylation of renal basement membranes and result in hyperproteinuria, hypercreatinemia, and increased urinary excretion of creatinine, urea, and uric acid. Normally, the kidney excretes creatinine and only low amount of low-molecular weight protein passes through the glomerulus, whereas urea and uric acid are reabsorbed by the proximal tubule. EMA showed significant (p<0.05) reduction of bilirubin, creatinine and elevation of protein levels than those of nondiabetic group, implying the presence of diabetic kidney disease with renal hyperfiltration due to STZ induction (Table 2). We observed that repeated treatment with EMA could
Table 1. Effect of *Morus alba* on blood glucose levels in STZ induced diabetic rats during different intervals of 12 weeks study period

<table>
<thead>
<tr>
<th>Treatment (mg/kg)</th>
<th>0 day</th>
<th>3 week</th>
<th>6 week</th>
<th>9 week</th>
<th>12 week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>108.23±2.71</td>
<td>97.16±1.21</td>
<td>101.66±3.19</td>
<td>99.33±2.03</td>
<td>96.23±4.79</td>
</tr>
<tr>
<td>D.Control</td>
<td>325±4.93</td>
<td>316.45±4.50</td>
<td>333.16±5.66</td>
<td>319.16±5.23</td>
<td>324.83±4.11</td>
</tr>
<tr>
<td>Standard</td>
<td>321.11±6.53</td>
<td>213.13±2.18</td>
<td>134.23±3.17</td>
<td>109.32±2.36</td>
<td>92.50±2.99</td>
</tr>
<tr>
<td>EMA (150 mg/kg)</td>
<td>297.65±3.68</td>
<td>223.83±4.23</td>
<td>146.35±3.60</td>
<td>121.33±3.99</td>
<td>98.60±1.66</td>
</tr>
<tr>
<td>EMA (300 mg/kg)</td>
<td>314.13±4.88</td>
<td>198.66±3.14</td>
<td>126.46±1.84</td>
<td>98.13±4.16</td>
<td>87.26±4.55</td>
</tr>
</tbody>
</table>

Number of rats per group = 6; data on each parameter were analyzed by one-way ANOVA followed by Dunnet’s test; *P* < 0.05, **P* < 0.01, ***P* < 0.001 as compared with diabetic control

Fig. 1. Effect of *Morus alba* on serum lipid levels in STZ induced diabetic rats at the end of 12 weeks study period

Fig. 2. Effect of *Morus alba* on renal lipid levels in STZ induced diabetic rats at the end of 12 weeks study period
attenuate hyperproteinuria, hypercreatininemia as well as ameliorate the loss of renal function and glomerular hyperfiltration in STZ-diabetic rats. Due to improved the filtration function and tubular reabsorption by EMA, urinary creatinine, urea, and uric acid level were controlled significantly p<0.05 (Table 3).

Oxidant stress markers (CAT, SOD, GSH and MDA), which are critical factors in the progression of diabetic nephropathy, are increased by inflammatory mechanisms of injury in the kidney. Among antioxidative enzymes, SOD catalyzes dismutation of the superoxide anion into hydrogen peroxide, while GSH both detoxifies hydrogen peroxides and converts lipid hydroperoxides to nontoxic alcohols; thus, antioxidant enzymes activities could reflect antioxidant defense status.

**Table 2.** Effect of *Morus alba* on serum parameters in STZ induced diabetic rats at the end of 12 weeks study period

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HbA1c (mg/kg)</th>
<th>T.Bilirubin (mg/dL)</th>
<th>Creatinine (mg/dL)</th>
<th>Total protein (mg/dL)</th>
<th>Albumin (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.09±0.23***</td>
<td>0.72±0.016*</td>
<td>0.68±0.02*</td>
<td>6.93±0.14*</td>
<td>3.35±0.09*</td>
</tr>
<tr>
<td>D.Control</td>
<td>11.43±0.56</td>
<td>1.78±0.042</td>
<td>1.92±0.03</td>
<td>3.88±0.34</td>
<td>7.20±0.10</td>
</tr>
<tr>
<td>Standard</td>
<td>3.42±0.16***</td>
<td>0.77±0.025*</td>
<td>0.69±0.02*</td>
<td>6.13±0.67*</td>
<td>3.86±0.06*</td>
</tr>
<tr>
<td>EMA (150mg/kg)</td>
<td>5.02±0.25*</td>
<td>0.92±0.016*</td>
<td>0.89±0.04*</td>
<td>7.90±0.24*</td>
<td>5.13±0.11*</td>
</tr>
<tr>
<td>EMA (300mg/kg)</td>
<td>4.16±0.54**</td>
<td>0.73±0.013*</td>
<td>0.71±0.03**</td>
<td>6.06±0.18*</td>
<td>3.99±0.12**</td>
</tr>
</tbody>
</table>

Number of rats per group = 6; data on each parameter were analyzed by one-way ANOVA followed by Dunnet’s test; *P< 0.05, **P< 0.01, ***P< 0.001 as compared with diabetic control

**Table 3.** Effect of *Morus alba* on urine parameters in STZ induced diabetic rats at the end of 12 weeks study period

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Creatinine (mg/dL)</th>
<th>Urine volume (ml/24hrs)</th>
<th>Ccr (ml/hrs)</th>
<th>Uric acid (mg/dL)</th>
<th>Urea (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.61±0.05</td>
<td>09.42±0.41</td>
<td>1.31±0.79</td>
<td>4.09±0.32</td>
<td>22.03±0.77</td>
</tr>
<tr>
<td>D.Control</td>
<td>1.68±0.03</td>
<td>26.52±0.85</td>
<td>6.61±0.49</td>
<td>8.72±0.18</td>
<td>39.46±0.94</td>
</tr>
<tr>
<td>Standard</td>
<td>0.69±0.04**</td>
<td>14.43±0.43*</td>
<td>1.84±0.11**</td>
<td>4.23±0.34*</td>
<td>26.89±0.77**</td>
</tr>
<tr>
<td>EMA (150mg/kg)</td>
<td>1.11±0.04*</td>
<td>18.17±0.32*</td>
<td>2.73±0.20*</td>
<td>5.79±0.21*</td>
<td>32.23±0.93*</td>
</tr>
<tr>
<td>EMA (300mg/kg)</td>
<td>0.65±0.04**</td>
<td>12.09±0.49*</td>
<td>1.89±0.21**</td>
<td>4.96±0.44*</td>
<td>27.13±0.87**</td>
</tr>
</tbody>
</table>

Number of rats per group = 6; data on each parameter were analyzed by one-way ANOVA followed by Dunnet’s test; *P< 0.05, **P< 0.01, ***P< 0.001 as compared with diabetic control

**Table 4.** Effect of *Morus alba* on antioxidant parameters in STZ induced diabetic rats at the end of 12 weeks study period

<table>
<thead>
<tr>
<th>Treatment</th>
<th>SOD (U/mg protein)</th>
<th>CAT (U/mg protein)</th>
<th>GSH (mg/100g tissue)</th>
<th>MDA (U/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>10.23±1.23</td>
<td>34.23±1.86</td>
<td>20.46±0.37</td>
<td>132.16±0.88</td>
</tr>
<tr>
<td>D.Control</td>
<td>4.65±1.01</td>
<td>17.64±1.34</td>
<td>15.65±0.17</td>
<td>246.79±2.13</td>
</tr>
<tr>
<td>Standard</td>
<td>9.46±0.89**</td>
<td>32.16±0.68***</td>
<td>21.13±0.26***</td>
<td>139.23±3.77***</td>
</tr>
<tr>
<td>EMA (150mg/kg)</td>
<td>7.26±0.74*</td>
<td>28.42±0.97**</td>
<td>20.11±0.41**</td>
<td>221.85±2.47*</td>
</tr>
<tr>
<td>EMA (300mg/kg)</td>
<td>10.16±1.06***</td>
<td>31.09±1.35**</td>
<td>20.16±0.74**</td>
<td>143.92±0.49***</td>
</tr>
</tbody>
</table>

Number of rats per group = 6; data on each parameter were analyzed by one-way ANOVA followed by Dunnet’s test; *P< 0.05, **P< 0.01, ***P< 0.001 as compared with diabetic control.
Fig. 3. Effect of *Morus alba* on histopathology of kidney

3A: Normal glomeruli and a compact tissue appearance with bowmans capsule (BC)3B: increased bowmans space (BS) and presence cellular infiltrates (CI) indicates cellular damage. 3C: Noticeable improvements in the tissue architecture were evident, and more visible glomeruli and fewer inflammatory cells were observed. 4D: absence of inflammatory cells, normal basement membrane.

**CONCLUSION**

In conclusion, *Morus alba* decreased blood glucose levels (hypoglycemia), normalizing the lipid levels in both serum and kidney (dyslipidemia), reduction in both serum and urine parameters and increased antioxidant enzymes activities (antioxidant) in diabetic rats. And consequently could alleviate diabetic nephropathy.

**REFERENCES**


